Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice

International Immunopharmacology

Volumn 20, Issue 2, 2014, Pages 283-289

  Su, Xiaoyan ^a   Pei, Zengyang ^a   Hu, Songhua ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Adjuvant effect; Ginsenoside Re; Rabies; Th1 Th2

Indexed keywords

GAMMA INTERFERON; GINSENOSIDE RE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RABVAC; UNCLASSIFIED DRUG; CYTOKINE; GINSENOSIDE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CD4 CD8 RATIO; CYTOKINE RELEASE; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CELL PROLIFERATION; DRUG EFFECTS; IMMUNIZATION; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; PANAX; RABIES; RABIES VIRUS; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CD4-CD8 RATIO; CELL PROLIFERATION; CYTOKINES; FEMALE; GINSENOSIDES; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED ICR; PANAX; RABIES; RABIES VACCINES; RABIES VIRUS; TH1 CELLS; TH2 CELLS; VACCINES, INACTIVATED;

EID: 84899027813     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.03.008     Document Type: Article

References (39)

1. B. Dietzschold, M. Schnell, and H. Koprowski Pathogenesis of rabies Curr Top Microbiol Immunol 292 2005 45 56
2. F.X. Meslin, D.B. Fishbein, and H.C. Matter Rationale and prospects for rabies elimination in developing countries Curr Top Microbiol Immunol 187 1994 1 26
3. D.W. Dreesen A global review of rabies vaccines for human use Vaccine 15 1997 S2 S6
4. D.L. Knobel, S. Cleaveland, P.G. Coleman, E.M. Fèvre, M.I. Meltzer, and M.E. Miranda et al. Re-evaluating the burden of rabies in Africa and Asia Bull World Health Organ 83 5 2005 360 368
5. C.E. Rupprecht A tale of two worlds: public health management decisions in human rabies prevention Clin Infect Dis 39 2 2004 281 283
6. R.L. Hu, A.R. Fooks, S.F. Zhang, Y. Liu, and F. Zhang Inferior rabies vaccine quality and low immunization coverage in dogs (Canis familiaris) in China Epidemiol Infect 136 11 2008 1556 1563
7. X. Wang, and J. Lou Two dynamic models about rabies between dogs and human J Biol Syst 16 04 2008 519 529
8. K. Bögel, and F.X. Meslin Economics of human and canine rabies elimination: guidelines for programme orientation Bull World Health Organ 68 3 1990 281 291
9. S. Cleaveland, M. Kaare, P. Tiringa, T. Mlengeya, and J. Barrat A dog rabies vaccination campaign in rural Africa: impact on the incidence of dog rabies and human dog-bite injuries Vaccine 21 17-18 2003 1965 1973
10. S.L. Davlin, and H.M. VonVille Canine rabies vaccination and domestic dog population characteristics in the developing world: a systematic review Vaccine 30 24 2012 3492 3502
11. X. Tang, M. Luo, S. Zhang, A.R. Fooks, R. Hu, and C. Tu Pivotal role of dogs in rabies transmission, China Emerg Infect Dis 11 12 2005 1970 1972
12. X. Wu, R. Hu, Y. Zhang, G. Dong, and C.E. Rupprecht Reemerging rabies and lack of systemic surveillance in People's Republic of China Emerg Infect Dis 15 8 2009 1159 1164
13. J. Zhang, Z. Jin, G.Q. Sun, T. Zhou, and S. Ruan Analysis of rabies in China: transmission dynamics and control PLoS One 6 7 2011 e20891
14. G. Sage, P. Khawplod, H. Wilde, C. Lobaugh, T. Hemachudha, and W. Tepsumethanon et al. Immune response to rabies vaccine in Alaskan dogs: failure to achieve a consistently protective antibody response Trans R Soc Trop Med Hyg 87 5 1993 593 595
15. J.M. Minke, J. Bouvet, F. Cliquet, M. Wasniewski, A.L. Guiot, and L. Lemaitre et al. Comparison of antibody responses after vaccination with two inactivated rabies vaccines Vet Microbiol 133 3 2009 283 286
16. S.G. Reed, S. Bertholet, R.N. Coler, and M. Friede New horizons in adjuvants for vaccine development Trends Immunol 30 1 2009 23 32
17. D.L. Lodmell, N.B. Ray, J.T. Ulrich, and L.C. Ewalt DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL) Vaccine 18 11-12 2000 1059 1066
18. C.P. Li, and R.C. Li An introductory note to ginseng Am J Chin Med 1 2 1973 249 261
19. X. Song, and S. Hu Adjuvant activities of saponins from traditional Chinese medicinal herbs Vaccine 27 36 2009 4883 4890
20. D. Kiefer, and T. Pantuso Panax ginseng Am Fam Physician 68 8 2003 1539 1542
21. W. Cho, W.S. Chung, S.K. Lee, A.W. Leung, C.H. Cheng, and K.K. Yue Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats Eur J Pharmacol 550 1-3 2006 173 179
22. Y.G. Wang, A.V. Zima, X. Ji, R. Pabbidi, L.A. Blatter, and S.L. Lipsius Ginsenoside Re suppresses electromechanical alternans in cat and human cardiomyocytes Am J Physiol Heart Circ Physiol 295 2 2008 H851 H859
23. E. Rivera, S. Hu, and C. Concha Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants Vaccine 21 11-12 2003 1149 1157
24. F. Su, L. Yuan, L. Zhang, and S. Hu Ginsenosides Rg1 and Re act as adjuvant via TLR4 signaling pathway Vaccine 30 27 2012 4106 4112
25. J. Sun, S. Hu, and X. Song Adjuvant effects of protopanaxadiol and protopanaxatriol saponins from ginseng roots on the immune responses to ovalbumin in mice Vaccine 25 6 2007 1114 1120
26. X. Song, J. Chen, K. Sakwiwatkul, R. Li, and S. Hu Enhancement of immune responses to influenza vaccine (H3N2) by ginsenoside Re Int Immunopharmacol 10 3 2010 351 356
27. L. Overbergh, D. Valckx, M. Waer, and C. Mathieu Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR Cytokine 11 4 1999 305 312
28. J.L. Yin, N.A. Shackel, A. Zekry, P.H. McGuinness, C. Richards, and K.V. Putten et al. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I Immunol Cell Biol 79 3 2001 213 221
29. T.B. Morrison, J.J. Weis, and C.T. Wittwer Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification Biotechniques 24 6 1998 954 958
30. M.W. Pfaffl A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 29 9 2001 e45
31. D. Qu, J. Han, and A. Du Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re Exp Parasitol 135 2 2013 234 239
32. I. Tizard Veterinary immunology: an introduction 5th ed. 1992 WB Saunders Philadelphia
33. C.L. Dorfmeier, A.G. Lytle, A.L. Dunkel, A. Gatt, and J.P. McGettigan Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection J Virol 86 21 2012 11533 11540
34. S.L. Constant, and K. Bottomly Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches Annu Rev Immunol 15 1 1997 297 322
35. M. Lafon, F. Megret, M. Lafage, and C. Prehaud The innate immune facet of brain J Mol Neurosci 29 3 2006 185 194
36. R. Edelman The development and use of vaccine adjuvants Mol Biotechnol 21 2 2002 129 148
37. J.M. Gottwein, T.G. Blanchard, O.S. Targoni, J.C. Eisenberg, B.M. Zagorski, and R.W. Redline et al. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization J Infect Dis 184 3 2001 308 314
38. I.A. Feria-Romero, K. Chávez-Rueda, S. Orozco-Suárez, F. Blanco-Favela, F. Calzada-Bermejo, and L. Chávez-Sánchez et al. Intranasal anti-rabies DNA immunization promotes a Th1-related cytokine stimulation associated with plasmid survival time Arch Med Res 42 7 2011 563 571
39. L.L. Perry, and D.L. Lodmell Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus J Virol 65 7 1991 3429 3434